SoliMix Clinical Study

Suliqua-logo

Lixilan-O study

SoliMix Study

Download this clinical summary to read about the benefits of Suliqua in the phase III SoliMix study. The study is demonstrating the benefits of Suliqua, a titratable fixed-ratio combination of insulin glargine + lixisenatide vs the mixed insulin BIAsp 30. This was done in Type 2 diabetes patients, inadequately controlled on basal insulin and metformin with or without an SGLT2i. 
Rosenstock J, et al. Diabetes Care. June 2021; dc210393

Lady talking on phone

Always up to date?

Webinars, evidence, expert videos, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com. Prescribing information will be available at the meeting.
This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close